Webinar
Latest Past Webinars
Failure is Not an Option – Understanding CCM® Therapy
This program will introduce CCM® therapy as a therapy option for treating NYHA Stage III Heart Failure patients that remain symptomatic despite being on optimal medical treatment. The faculty will explain and break down the mechanism of action of cardiac contractility modulation. The faculty will discuss the screening process for eligible CCM patients from the EP and HF clinical workflow perspectives. Utilizing their personal experience, our thought leaders will explore and describe their experience with CCM and illustrate real-life patient responses to the therapy. The session will also offer case studies to demonstrate processes and outcomes. Lastly, we will allow time for questions and answers to encourage participation and foster a valuable discussion.
Setting the Stage for CCM® – From Screening to Implant (a Case Based Approach)
November 17th, 2021 6:00pm – 7:15pm EDTREGISTER NOWSetting the Stage for CCM® — From Screening to Implant (Case-Based Approach) This program will introduce CCM® therapy therapy through the eyes of implanting electrophysiologists. Using their own clinical cases, program faculty will discuss the screening process for eligible CCM patients, the implant procedure, lead placement, and patient follow-up. Each faculty member will […]
Failure is Not an Option: Implementing CCM® from a HF and EP Perspective
Heart Failure is a progressive condition, and medical management strategies for this patient population has evolved over the years. This program will introduce CCM® therapy, review the action mechanism, and how the treatment works at the myocardial level. The faculty will review the clinical safety data surrounding the therapy as well as the indications for use. Evaluation and screening of patients that continue to be symptomatic from their heart failure indications despite being on guideline-directed medical treatment continue to be a challenge on all levels. Our faculty will discuss screening best practices, from both an electrophysiology and heart failure perspective, and how to establish a baseline for patients while giving them access to CCM® therapy that they may qualify to undertake.
